Skip to main content

Table 4 In-hospital management of the 216 included patients, and comparison according to the consumption of anti-inflammatory drugs prior to admission

From: Impact of anti-inflammatory drug consumption in peritonsillar abscesses: a retrospective cohort study

  Total population No AID AID AID vs. no AID NSAID NAID vs. no AIDa CT Corticosteroids vs. no AIDa NSAID vs. corticosteroidsa
p-value p-value p-value p-value
n 216 89 (41.2 %) 127 (58.7 %)   76 (35.2 %)   67 (31.0 %)   
Paraclinical tests
 CT-scan 77 (35.6 %) 38 (42.7 %) 39 (30.7 %) 0.070 23 (30.3 %) 0.305 19 (28.4 %) 0.185 0.842
  Abscess volume (cm3) 4.4 (1.6–10.2) 2.9 (0.9–7.8) 6.8 (3.7–12.7) 0.005 5.7 (3.2–10.6) 0.028 7.1 (1.9–13.5) 0.049 0.728
 CRP (mg/L) 90.0 (44.4–156.5) 109.5 (66.9–172.8) 72.4 (38.3–133.0) 0.002 95.1 (50.9–181.0) 0.663 47.5 (26.5–81.5) <10−3 <10−3
 WBC (/mm3) 14,400 (12,100–17,700) 13,500 (12,000–16,200) 15,400 (12,50–18,300) 0.031 15,600 (12,600–17,700) 0.131 15,500 (12,500–19,100) 0.111 0.605
 Neutrophils (/mm3) 13,600 (10,100–16,200) 12,800 (9400–15,600) 14,100 (10,400–16,500) 0.326 14,200 (11,300–15,600) 0.437 14,100 (10,300–17,000) 0.454 0.927
Hospitalisation 215 (99.5 %) 88 (98.9 %) 127 (100.0 %) 0.412 76 (100.0 %) 1.000 67 (100.0 %) 1.000 NC
 Hospital stay (d) 3.0 (3.0–4.0) 3.0 (3.0–4.0) 3.0 (3.0–4.0) 0.170 3.0 (3.0–4.0) 0.492 3.0 (3.0–4.0) 0.066 0.344
 ICU 3 (1.4 %) 1 (1.1 %) 2 (1.6 %) 1.000 2 (2.6 %) 0.565 0 (0.0 %) 1.000 0.499
Surgical management 203 (94 %) 83 (93.3 %) 120 (94.5 %) 0.708 73 (96.1 %) 0.740 63 (94 %) 1.000 0.539
 Puncture/Incision 199 (92.1 %) 82 (92.1 %) 117 (92.1 %) 0.998 71 (93.4 %) 0.918 62 (92.5 %) 0.693 0.787
 Productive puncture 152 (70.4 %) 56 (62.9 %) 96 (75.6 %) 0.045 58 (76.3 %) 0.268 53 (79.1 %) 0.160 0.831
  Initial 199 (92.1 %) 82 (92.1 %) 117 (92.1 %) 0.998 71 (93.4 %) 0.918 62 (92.5 %) 0.758 0.787
  Secondary 80 (37 %) 34 (38.2 %) 46 (36.2 %) 0.767 31 (40.8 %) 0.849 24 (35.8) 0.294 0.419
 Surgery under GA 21 (9.7 %) 9 (10.1 %) 12 (9.4 %) 0.871 10 (13.2 %) 0.982 6 (9.0 %) 0.328 0.217
  Initial 5 (2.3 %) 1 (1.1 %) 4 (3.1 %) 0.330 3 (3.9 %) 0.346 2 (3.0 %) 1.000 1.000
  Secondary 18 (8.3 %) 8 (9.0 %) 10 (7.9 %) 0.806 9 (11.8 %) 0.836 4 (6.0 %) 0.155 0.122
  Cervicotomy 2 (0.9 %) 0 (0.0 %) 2 (1.6 %) 0.513 2 (2.6 %) 0.161 0 (0.0 %) NC 0.499
  Tonsillectomy 12 (5.6 %) 4 (4.5 %) 8 (6.3 %) 0.765 7 (9.2 %) 0.715 4 (6.0 %) 0.653 0.372
 Iterative procedure 93 (43.1 %) 39 (43.8 %) 54 (42.5 %) 0.849 38 (50.0 %) 0.887 27 (40.3 %) 0.147 0.142
Medical management
 IV antimicrobial therapy 214 (99.1 %) 88 (98.9 %) 126 (99.2 %) 1.000 75 (98.7 %) 0.410 66 (98.5 %) 1.000 NC
 Total duration (d) 12.5 (11.0–15.0) 12.0 (11.0–15.0) 13.0 (10.0–16.0) 0.249 12.0 (10.0–15.3) 0.203 14.0 (12.0–17.5) 0.046 0.007
 From hospital admission (d) 10.0 (10.0–11.0) 10.0 (10.0–12.0) 10.0 (10.0–11.0) 0.021 10.0 (10.0–11.0) 0.204 10.0 (10.0–11.0) 0.008 0.176
  1. Data are presented as n (%) for dichotomic variables and median (IQR) for continuous variables. For the calculation of each percentage, the number of missing values was excluded from the denominator. The two groups were compared by non-parametric tests (chi-square test, Fisher exact test and Mann–Whitney U-test), as appropriate
  2. AID anti-inflammatory drug, CRP C-reactive protein, CT-scan, computed tomography scan, d days, GA general anesthesia, ICU Intensive care unit, IV intravenous, NSAID non-steroidal anti-inflammatory drug, WBC white blood cell
  3. aExcluding patients receiving both NSAIDs and CT